JP2012140442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012140442A5 JP2012140442A5 JP2012036919A JP2012036919A JP2012140442A5 JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5 JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- pathway
- dna
- treated
- initial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55357804P | 2004-03-15 | 2004-03-15 | |
| US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503972A Division JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014091125A Division JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012140442A JP2012140442A (ja) | 2012-07-26 |
| JP2012140442A5 true JP2012140442A5 (https=) | 2013-04-04 |
Family
ID=34993432
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Ｓｎｓ−５９５、及びその使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Ｓｎｓ−５９５、及びその使用方法 |
| JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Ｓｎｓ−５９５、及びその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (12) | US7968565B2 (https=) |
| EP (4) | EP3053579A1 (https=) |
| JP (9) | JP5096913B2 (https=) |
| KR (1) | KR101169825B1 (https=) |
| CN (5) | CN104324029A (https=) |
| AT (2) | ATE451924T1 (https=) |
| AU (3) | AU2005222607B2 (https=) |
| BR (1) | BRPI0508700A (https=) |
| CA (3) | CA2954578A1 (https=) |
| CY (2) | CY1109741T1 (https=) |
| DE (2) | DE602005018333D1 (https=) |
| DK (3) | DK1729770T3 (https=) |
| ES (3) | ES2334802T3 (https=) |
| HU (1) | HUE027266T2 (https=) |
| IL (2) | IL177946A (https=) |
| MX (2) | MX349188B (https=) |
| NO (3) | NO338058B1 (https=) |
| NZ (2) | NZ549557A (https=) |
| PL (3) | PL1729770T3 (https=) |
| PT (2) | PT1729770E (https=) |
| SI (2) | SI1725233T1 (https=) |
| WO (2) | WO2005089756A1 (https=) |
| ZA (1) | ZA200607248B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324029A (zh) | 2004-03-15 | 2015-02-04 | 逊尼希思制药公司 | Sns-595及其使用方法 |
| US7652134B2 (en) * | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| EP1802306A2 (en) * | 2004-09-17 | 2007-07-04 | Cylene Pharmaceuticals, Inc. | Quinolone analog as cell proliferation inhibitors |
| EP1926372A2 (en) * | 2005-08-19 | 2008-06-04 | Cylene Pharmaceuticals, Inc. | HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF |
| US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| KR20080041298A (ko) * | 2005-09-02 | 2008-05-09 | 선에시스 파마슈티컬스 인코포레이티드 | 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법 |
| JP5374153B2 (ja) * | 2005-09-02 | 2013-12-25 | サネシス ファーマシューティカルズ， インコーポレイテッド | 癌の治療のための（＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸を使用する方法 |
| CN101505753B (zh) * | 2006-06-12 | 2014-05-21 | 逊尼希思制药公司 | 治疗癌症的化合物和组合物 |
| US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| US20080063642A1 (en) * | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
| US20090093513A1 (en) * | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| CN103720701A (zh) * | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
| AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
| EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| KR20170090535A (ko) * | 2008-12-31 | 2017-08-07 | 선에시스 파마슈티컬스 인코포레이티드 | (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법 |
| SG10201400258SA (en) * | 2009-02-27 | 2014-05-29 | Sunesis Pharmaceuticals Inc | Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| TW201120037A (en) * | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
| AU2012372081B2 (en) | 2012-02-27 | 2017-06-08 | Agq Technological Corporate S.A. | Monitoring and control of soil conditions |
| JP6378171B2 (ja) | 2012-04-24 | 2018-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤 |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
| US20160136173A1 (en) * | 2013-07-02 | 2016-05-19 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - III |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| WO2025033367A1 (ja) * | 2023-08-04 | 2025-02-13 | 湧永製薬株式会社 | 抗腫瘍剤併用療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
| US216316A (en) * | 1879-06-10 | Improvement in latches | ||
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| CN1053668C (zh) | 1994-06-14 | 2000-06-21 | 大日本制药株式会社 | 新型化合物及其制法和抗肿瘤剂 |
| JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| PT966683E (pt) * | 1997-01-13 | 2003-08-29 | Kudos Pharm Ltd | Ensaios agentes terapia e diagnostico relativos a modulacao de actividade de reparacao de adn celular |
| US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
| CA2293724C (en) | 1997-06-05 | 2010-02-02 | Xiaodong Wang | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| US6171857B1 (en) | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
| JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
| JP2002519010A (ja) * | 1998-06-30 | 2002-07-02 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｄｎａ−ｐｋの使用法 |
| US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
| CA2363621A1 (en) * | 1999-02-26 | 2000-08-31 | The Johns Hopkins University | A novel inhibitor of programmed cell death |
| US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
| AU2001256530A1 (en) * | 2000-05-20 | 2001-12-03 | Cancer Research Technology Limited | Drug screening systems and assays |
| WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2002028387A1 (en) | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| CA2426762A1 (en) | 2000-11-02 | 2002-05-10 | Sloan-Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| AU2003253593A1 (en) * | 2002-04-05 | 2003-11-03 | Richard A. Fishel | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| CA2523178C (en) | 2003-03-24 | 2012-10-23 | Luitpold Pharmaceuticals, Inc. | Materials and methods to potentiate cancer treatment |
| CN104324029A (zh) * | 2004-03-15 | 2015-02-04 | 逊尼希思制药公司 | Sns-595及其使用方法 |
| KR20080041298A (ko) | 2005-09-02 | 2008-05-09 | 선에시스 파마슈티컬스 인코포레이티드 | 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법 |
| US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| CN101505753B (zh) | 2006-06-12 | 2014-05-21 | 逊尼希思制药公司 | 治疗癌症的化合物和组合物 |
| US20100048609A1 (en) | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| US20080063642A1 (en) | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
| CN103720701A (zh) | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
| EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
| KR20170090535A (ko) | 2008-12-31 | 2017-08-07 | 선에시스 파마슈티컬스 인코포레이티드 | (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법 |
| SG10201400258SA (en) | 2009-02-27 | 2014-05-29 | Sunesis Pharmaceuticals Inc | Methods Of Using SNS-595 For Treatment Of Cancer Subjects With Reduced BRCA2 Activity |
| CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
| UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es not_active Expired - Lifetime
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en not_active Ceased
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en not_active Ceased
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko not_active Expired - Fee Related
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es not_active Expired - Lifetime
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Expired - Lifetime
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de not_active Expired - Lifetime
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es not_active Expired - Lifetime
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Expired - Lifetime
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de not_active Expired - Lifetime
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Expired - Lifetime
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012140442A5 (https=) | ||
| EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
| EP3083658A4 (en) | Methods and assays relating to circulating tumor cells | |
| EP2816141A4 (en) | ELECTROLYSIS CELL AND ELECTROLYSIS TANK | |
| WO2013006490A3 (en) | Antibodies that specifically bind to tim3 | |
| HUE036147T2 (hu) | Adoptív sejtterápiában hasznos polipeptidek | |
| HRP20160854T1 (hr) | Oligonukleotidi za izradu promjena u sekvenci ciljne rna molekule prisutne u živoj stanici | |
| IL238476B (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| SI2494039T1 (sl) | Postopek reprogramiranja celic in njihova uporaba | |
| HUE049171T2 (hu) | Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek | |
| IL240252B (en) | Solid substrates for promoting cell and tissue growth | |
| CL2015000084A1 (es) | Célula huésped, particularmente de hongo filamentoso, deficiente en la producción de proteína agse; y método de producción de la célula. | |
| HK1206055A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| BR112014005355A2 (pt) | células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença | |
| CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| Casals et al. | Next-generation sequencing approaches for genetic mapping of complex diseases | |
| ZA201406726B (en) | Methods and composition related to brown adipose-like cells | |
| PL2646544T3 (pl) | Sposób przygotowania drożdży przemysłowych, drożdże przemysłowe i zastosowanie do wytwarzania etanolu z przynajmniej jednej pentozy | |
| EP3009502A4 (en) | Cell culture equipment coated with laminin fragments in dry state | |
| CL2014003382A1 (es) | Composición alimenticia concentrada en forma de gel; y su proceso de preparacion. | |
| SI2859092T1 (sl) | Terapevtsko cepivo za zdravljenje diabetesa tipa 1 pri otrocih, uporaba naprave za sortiranje celic in postopek multipliciranja TREG celic za pridobivanje terapevtskega cepiva za zdravljenje diabetesa tipa 1 | |
| HUE038546T2 (hu) | Száraz helyiség, különösen lítium-ion cellagyártásnál történõ alkalmazásra | |
| EP2903029A4 (en) | POLYMERIC SOLAR CELL AND METHOD FOR PREPARING THE SAME | |
| EP2912164A4 (en) | MICRO-RNAS AND CELL PROGRAMMING |